Let the alcohol dry completely before injecting, as wet alcohol stings
Without adequate blood supply, healing stalls regardless of other favorable conditions

this off-label use is not backed by the same level of controlled human trial evidence as the lipodystrophy indication Known risks and side effects: Injection site reactions, including erythema, pruritus, pain, and bruising at the injection site Arthralgia (joint pain) and peripheral edema (fluid retention), recognized class effects of GH-axis stimulation Increases in blood glucose and reduced insulin sensitivity, with clinical trials showing a higher rate of elevated HbA1c and new-onset hyperglycemia versus placebo Formation of anti-tesamorelin antibodies, reported in a substantial proportion of treated patients, with unclear long-term clinical significance Contraindicated in people with active malignancy, pituitary or hypothalamic disruption, or pregnancy, per FDA labeling Evidence snapshot: The strongest evidence is a set of Phase 3 human randomized controlled trials that supported FDA approval of tesamorelin for reducing visceral abdominal fat in HIV-associated lipodystrophy (approved 2010), plus a separate placebo-controlled human RCT (Baker et al., 2012, Archives of Neurology) showing improved executive function in older adults

Start low: Begin around 250 g daily for 12 weeks Increase gradually: Up to 500 g twice daily if tolerated Cycle: 46 weeks on, then take 24 weeks off This approach supports tendon, muscle, or ligament healing without overloading the system
how they translate across routes is an open research question, not a solved one
Some medicines might interact with the vitamins in the injection